Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March
March 06 2019 - 7:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology
company developing novel cancer immunotherapies based on
tumor-infiltrating lymphocyte (TIL) technology, today announced
that company management will participate and present at the
following investors conferences in March:
- Cowen and Company 39th Annual Health Care
Conference in Boston, March 11-13, 2019
Location: Boston Marriott Copley PlaceDate/Time: Wednesday,
March 13, at 8:00 a.m. EDTA live and archived webcast of the
presentation will be available by visiting the Investors section of
Iovance Biotherapeutics' website at http://ir.iovance.com.
- Oncology Investor Conference in Boston, March
14-15, 2019
Location: 28 State StreetDate/time: Thursday, March 14, at 3:30
p.m. EDT
- Oppenheimer 29th Annual Healthcare Conference
in New York, March 19-20, 2019
Location: The Westin New York Grand CentralDate/Time: Tuesday,
March 19, at 8:00 a.m. EDTA live and archived webcast of the
presentation will be available by visiting the Investors section of
Iovance Biotherapeutics' website at http://ir.iovance.com.
- Alliance for Regenerative Medicine (ARM) 7th Annual
Cell & Gene Therapy Investor Day in New York on March
21, 2019
Location: The Metropolitan ClubDate/Time: Thursday, March 21, at
11:25 a.m. EDT
- China Healthcare Investment Conference (CHIC)
in Shanghai, China on March 26-28, 2019
Location: The Ritz-Carlton Shanghai, PudongDate/Time: Thursday,
March 28, at 9:00 a.m. China Standard Time (CST)
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell
therapy using tumor-infiltrating lymphocyte (TIL) technology that
amplifies the body’s own immune response to eradicate solid tumors
or attack blood cancers. The company’s lead candidates are being
investigated for the treatment of patients with locally advanced,
recurrent or metastatic cancers including melanoma and cervical,
head and neck, and non-small cell lung cancer. For more
information, please visit www.iovance.com.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024